PRAXIS PRECISION MEDICINES I (PRAX) Stock News

USA - Nasdaq - NASDAQ:PRAX - US74006W2070 - Common Stock

247.99 USD

+58.02 (+30.54%)

Last: 12/5/2025, 8:00:00 PM

255 USD

+7.01 (+2.83%)

After Hours: 12/5/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PRAX Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Chartmill - Mentions: WHLR SPWH DOMO PSN ...

News Image

What's going on in today's session

2 days ago - By: Chartmill - Mentions: IRBT WHLR SPWH DOMO ...

News Image

Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session.

2 days ago - By: Chartmill - Mentions: IRBT WHLR SPWH DOMO ...

News Image

The market is filled with gapping stocks in Friday's session.

2 days ago - By: Chartmill - Mentions: AGX WHLR SPWH TSE ...

News Image

What's going on in today's pre-market session

2 days ago - By: Stocktwits - Mentions: NET

Why Did PRAX Stock Rocket 24% Pre-Market Today?

2 days ago - By: Benzinga

Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?

2 days ago - By: Stocktwits - Mentions: SPY QQQ DIA NFLX ...

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar

2 days ago - By: Chartmill - Mentions: VNDA COO AGX ONCY ...

News Image

Curious about the stocks that are showing activity after the closing bell on Thursday?

2 days ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

2 days ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

2 days ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

2 days ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

3 days ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 days ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 days ago - By: Praxis Precision Medicines, Inc.

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

12 days ago - By: Praxis Precision Medicines, Inc.

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

16 days ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

16 days ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

17 days ago - By: Benzinga

Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'

17 days ago - By: Stocktwits - Mentions: IWMW AVUS

News Image

Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position

a month ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

a month ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

a month ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results

a month ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results

a month ago - By: Praxis Precision Medicines, Inc.

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback

a month ago - By: Zacks Investment Research - Mentions: PTCT

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy?

a month ago - By: The Motley Fool

Meet the Biotech Stock That Just Jumped 251% Higher

2 months ago - By: Stocktwits

Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win

2 months ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

2 months ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

2 months ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

2 months ago - By: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Proposed Public Offering